|
| REVIEW ARTICLE |
|
| Year : 2010 | Volume
: 2
| Issue : 1 | Page : 2-7 |
 |
|
Patent protection strategies
Himanshu Gupta1, Suresh Kumar1, Saroj Kumar Roy2, RS Gaud2
1 Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110 062, India
2 School of Pharmacy and Technology Management, SVKM's NMIMS University, Mumbai-56, India
| Date of Submission | 25-Jan-2010 |
| Date of Decision | 15-Feb-2010 |
| Date of Acceptance | 25-Feb-2010 |
| Date of Web Publication | 23-Apr-2010 |
Correspondence Address:
Himanshu Gupta
Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110 062
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0975-7406.62694
 Abstract | | |
It is widely recognized that the pharmaceutical industry faces serious financial challenges. Large numbers of blockbuster drugs are losing patent protection and going generic. The pipeline of new drugs is too sparse to fill the gap and generate a platform for future growth. Moreover, many of the new products are biologics with much narrower target patient populations and comparatively higher prices relative to traditional pharmaceuticals. So now the time has come for pharmaceutical scientists to have a better understanding of patent fundamentals. This need is illustrated by analyses of key scientific and legal issues that arose during recent patent infringement cases involving Prozac, Prilosec, and Buspar. Facing this scenario, the pharmaceutical industry has moved to accelerate drug development process and to adopt at the same time different strategies to extend the life time of the patent monopoly to provide the economic incentives and utilizing it for drug discovery and development. This review covers the need of patent protection and various strategies to extend the patent. Keywords: Expiration, patent, pharmaceutical, racemate, strategies
How to cite this article:
Gupta H, Kumar S, Roy SK, Gaud R S. Patent protection strategies. J Pharm Bioall Sci 2010;2:2-7 |
A patent is a legal device that grants an inventor market exclusivity over a new invention or medication. Market exclusivity can mean tremendous economic rewards for the patent holder because it provides the inventor with a monopoly over the invention for the 20-year patent term. Obtaining a patent and retaining market exclusivity can be a treacherous process, especially in the arena of pharmaceutical patents. Pharmaceutical companies today are facing increased costs for drug discovery and development and aggressive competition from generic drug companies [Table 1]. As research costs skyrocket, generic drug companies sit poised and are ready to compete as soon as a patent expires [Table 2]. Maximizing patent term for successful products is an effective strategy for fending off generic competition and extending product lifecycle. Patents grant the creators of new inventions exclusive control and possession over these inventions. This allows the inventor to prevent others from commercially using ideas or inventions without the creator's permission during the life of the patent. [1] Scientific, legal, and practical considerations must be carefully weighed to best protect an inventor's rights. Creating and protecting or attacking pharmaceutical patents requires close interaction between pharmaceutical scientists and lawyers. It also requires a good understanding of key concepts of each other's discipline. Therefore, there should be collaboration between scientists and attorneys. [2],[3]
The division of labor can be summarized as 'Scientists invent, Lawyers patent.' However these two groups do not communicate effectively because there is a general lack of understanding of each culture, and these interactions often lead to a cognitive friction that is both disturbing and costly to the society. [4]th
| Market Exclusivity | |  |
The quest for market exclusivity [1]0 is the engine that drives patent legislation and litigation. Market exclusivity describes the crucial period of time, usually 20 years, when an entity enjoys an economic monopoly on its invention. These two decades of market exclusivity can bestow huge economic rewards for any inventor, and are extremely critical to the success of pharmaceutical companies in both profitability and recuperating invested capital. Market exclusivity also provides a vital incentive for continued development of new inventions. Without patent protection, the pharmaceutical company is unlikely to invest the capital needed to develop innovative medications. Diminished patent protection will reduce innovative desire to develop new and potentially better drugs and treatments, which in turn could result in the use of more expensive treatments. Market exclusivity has become even more critical in recent years due to a decline in innovative theories and formulations. For instance, pharmaceutical innovation has drastically declined and is concurrent with an extreme escalation in research costs. In turn, skyrocketing research costs have resulted in an increased dependence on market exclusivity as a means of maintaining growth and profitability.
| Rising Costs of Drug Development | | |
The costs associated with discovering a compound, turning this discovery into a suitable drug candidate, and getting it to market, have risen dramatically. Some estimates indicate that the cost for developing and marketing a single pharmaceutical product has risen from $54 million in the 1970s to greater than $800 million by 2000. [5] Patent protection and the market exclusivity that comes with it help to ensure a return on investment. A patent holder has the right to exclude others from making, using, and selling the patented invention for a defined period. Therefore, patented drugs are temporarily safe from the competition of generics, often resulting in substantial revenues. For example, US sales of Prilosec in 2000 were over $4 billion [6] and worldwide sales of on-patent Lipitor and Prevacid totaled over $9.2 billion and $2.5 billion, respectively, in 2003. [7] During the last couple of years, a remarkable number of patented 'blockbuster' drugs lost their protection [Table 3]. When Eli Lilly's patents for Prozac (Fluoxetine) expired in 2001, the concomitant multimillion dollar losses in revenue demonstrated the devastating impact of patent expiration .
The process of obtaining a patent begins when an inventor files a patent application in the United States Patent and Trademark Office (USPTO). [3] It is important to file a patent application as soon as practicable because the first person to file gains priority over all others who claim rights to the same invention. The application describes the invention, gives examples of how it can be used, and usually includes illustrations like schematic drawings or graphs. Filing swiftly and also thoroughness are important. The inventor cannot add new information once he or she has already filed a patent application. [Figure 1] illustrates the patent application process. A registered patent attorney/agent or an inventor acting pro se files a utility patent application with the USPTO. A USPTO examiner with technical training in the field of the invention conducts a prior art search and determines whether the application satisfies the legal requirements for patentability. The examiner issues an 'office action' setting forth the grounds for rejection. The applicant or his/her representative responds by amending the claims, submitting arguments, or doing both to overcome the rejections. The reviews the response and (1) allows the claim or (2) issues another office action. This 'back and forth' with the USPTO continues until the examiner issues a 'Notice of Allowance' or the applicant abandons the application. If necessary, the examiner's decision may be appealed to the Board of Patent Appeals and interferences and then to a federal court. Issuance of the patents confers on the applicant the right to exclude others from making, using, selling the claimed invention for 20 years from the date the earliest application was filed. Patent rights are maintained by the payment of maintenance fees at 3.5, 7.5, and 11.5 years from the issue date.
| Strategies for Extending Drug Commercial Lifecycle | | |
A company intending to market a generic version of a listed drug must certify one of the following regarding the patents listed in connection with the innovator's New Drug Application NDA [6],[7] : (1) It has not been patented; (2) the applicable patent has expired; (3) the patent will expire on a given date and that the generic version will not be marketed before that date; or (4) the listed patent is not infringed or invalid. The generic company is also required to notify the innovator about the abbreviated NDA (ANDA) filing and explain the reasons why it believes the generic version will not infringe the listed patent or the listed patent is invalid.
Pharmaceutical companies can employ a number of strategies to maximize patent protection on important compounds, thereby maximizing the commercial lifecycle. During the research and development phase of drug discovery, a company will typically obtain patent protection for the general compound and a method likely to be used with the compound in the treatment or prevention of a particular disease or condition. Once a compound or pharmaceutical composition has been patented, that patent becomes a prior art reference that must be considered when seeking additional patent protection around the compound or pharmaceutical. As a result, the new patent protection generally encompasses narrow improvements or new uses for the pharmaceutical not disclosed or suggested in the original patent. Strategies for maximizing patent term are described below briefly.
New formulations
One means of extending patent protection for a commercially successful drug is to obtain additional patents covering new formulations of the known compound clinically superior to the previous drug formulation. Developing and patenting new formulations that promote patient compliance through reduced dosing or ease of use, or that exhibit improved therapeutic outcomes or more favorable side-effect profiles, is particularly advantageous for defending against generics and protecting market share. Moreover, new formulations, as long as being sufficiently similar to the original approved drug, have the additional advantage of a shorter Food and Drug Administration FDA approval route.
Examples include sustained-release formulations of existing drugs. When Lilly faced the expiration of its patent for the blockbuster antidepressant drug Prozac, the company developed and obtained patent protection and FDA approval for a once-weekly, sustained-release Fluoxetine formulation. Bristol-Myers Squibb also obtained patent protection and FDA approval for its extended-release formulation of the diabetes drug Glucophage (Metformin hydrochloride). Marketed under the brand name Glucophage XR, this new formulation permits once-daily dosing for type II diabetics. [8]
New routes of administration for known drugs
Additional patent protection can also be obtained for new formulations that permit new routes of administration for known drugs. The migraine treatment drug Imitrex (Sumatriptan) accounts for more than $1 billion in annual sales for GlaxoSmithKline [GSK]. The patent directed to the original compound is set to expire in 2006, so in an effort to extend patent protection and maintain its market share, GSK has developed and obtained FDA approval and patents directed to Imitrex formulations for intranasal delivery. [9]
Stereoselectivity/chiral switches
Two thirds of the drugs presently in the market are chiral drugs, which means that of the two forms one is good the other is ineffective or even dangerous. [10] An additional issue has recently emerged involving enantiomeric drugs (drugs made up of two mirror-image molecules that have the same chemical composition) derived from racemate pharmaceuticals for which a company already holds a patent. [11] Many drugs are compounds made up of different mixtures of stereoisomers, and such mixtures can consist of either enantiomers or isomers. A 'racemate' or 'racemic mixture' is a compound consisting of an equal mixture of pairs of enantiomers. Many companies holding a patent nearing expiration for a racemic drug choose to remarket the drug as a single enantiomer under a different patent. This process of 'racemic switching,' allows drug companies to apply for FDA approval of the enantiomer, before the expiration of the racemic patent, while maintaining market exclusivity for the drug as a whole. Due to the fact that the enantiomer pharmaceutical sales reached $160 billion in 2002, racemic switching has become another valuable topic of discussion in the biotech patent arena [12] [Table 4].
Potential advantages of single enantiomer products
There are several advantages of single enantiomer products. [13]Some of them are (1) less complex, more selective pharmacodynamic profile, (2) potential for an improved therapeutic index, (3) less complex pharmacokinetic profile, (4) reduced potential for complex drug interactions, and (5) less complex relationship between plasma concentration and effect. One of the success stories in exploiting chirality is Prilosec (Omeprazole). The basic patent for this blockbuster acid-reflux drug expired in 2002. In an effort to retain its share of the lucrative gastrointestinal drug market, Astra Zeneca began searching for a 'better' Omeprazole years before the patent was set to expire. The result was the synthesis of the single (S) enantiomer of Omeprazole, Esomeprazole, which exhibits superior clinical efficacy and better bioavailability than the original drug. Esomeprazole is marketed as Nexium for the treatment of acid-reflux disease and accounted for nearly $3 billion sales in 2003. [14]
New uses
In addition to patent protection for the original compound and method of use, patents directed to new uses and treatment indications can be obtained. Developing new methods of use for identified compounds can be a successful strategy for maximizing research dollars and for increasing the commercial life. [15],[16],[17]
Several pharmaceutical companies have successfully obtained patent protection for new methods of use. For example, Merck originally developed, patented, and marketed Finasteride for treatment for benign prostate enlargement under the brand name Proscar. Additional patent protection and FDA approval were sought when a new use for Finasteride - treating male pattern baldness - was identified. Finasteride for the treatment of hair loss is marketed under the brand name Propecia. Similarly, the compound Atomoxetine was patented in the early 1980s by Lilly and initially investigated as a treatment for depression. Further research and development of Atomoxetine led to the identification of a new use for this compound in the treatment of attention deficit hyperactivity disorder. Lilly has obtained patent protection and FDA approval for this new use, marketing it as Strattera. More than 2 million prescriptions for Strattera were written in its first 9 months in the market. [18],[19],[20]Ideally, more than one of these approaches should be employed to extend patent protection. For example, in addition to developing a once-weekly formulation, Lilly sought to minimize its losses from the expiration of the Prozac patent by obtaining a patent and FDA approval for a new medical use of Fluoxetine in the treatment of premenstrual dysphoric disorder (PMDD). Lilly markets Fluoxetine for PMDD as Sarafem and has secured patent protection until 2007 for this new indication. Bupropion, the GSK drug that was reformulated into a sustained-release formulation, was also shown to aid in smoking cessation. GSK has secured additional patent protection for this new indication and for pharmaceutical formulations for this new use, which GSK markets under the brand name Zyban. Therefore, by developing and patenting both new formulations and new uses for known drugs, Lilly and GSK have enhanced their opportunities for maximizing patent protection for these drugs. [21],[22]
Combinations
Does one and one make three? That is the question drug companies are asking themselves these days as they face huge threats to their earnings from patent expirations. One novel solution: combining two or more successful drugs into one tablet and marketing it as a whole new product.
Schering-Plough is looking to extend its giant franchise in its allergy drug Claritin by combining it with Singulair, an asthma drug from Merck. Schering-Plough is not alone. Eli Lilly, Pfizer, and Warner-Lambert are all looking to create new combinations of drugs to bolster earnings and sustain growth. Companies are getting a lot more creative in ways to sustain the product lifespan of drugs. The medical community looks at it as a kind of cookbook medicine. They have an aversion to combination drugs. Nonetheless, it is a strategy that has proved successful for some drug makers [23] [Table 5].
Lilly has FDA approval and an active patent for Olanzapine (Zyprexa) to treat schizophrenia. As noted above, the patent for the FDA-approved drug Fluoxetine (Prozac) for treating depression has expired. To extend the lifecycle of Zyprexa and to recoup losses due to the market entry of generic Fluoxetine, Lilly has developed and patented a combination product called Symbyax comprising Olanzapine and Fluoxetine, for the treatment of bipolar disorder. Zyprexa accounted for more than $1 billion in sales in 2003, and the combination product Symbyax is expected to add $100 million in sales to the Zyprexa product line. [24] Developing treatments for HIV infection has been a research focus of GSK for two decades. GSK owns patents directed to pharmaceutical formulations of AZT, Lamivudane, and Abacavir sulfate, which it markets as individual products under the brand names Retrovir, Epivir, and Ziagen, respectively. All patents directed to pharmaceutical formulations comprising AZT alone will expire in early 2005. To extend its AZT line of products beyond the basic patent terms, GSK obtained additional patents directed to AZT in combination with its other HIV drugs. GSK markets the combination of AZT and Lamivudane under the brand name Combivir for the treatment of HIV infection. A second combination of AZT, Lamivudane, and Abacavir sulfate is sold as Trizivir. Combivir and Trizivir together generated more than $1 billion in sales in 2003.
Polymorphism
Polymorphism has also presented a scientifically challenging issue for biotech companies and a legally challenging one for the courts. Polymorphism is the concept of a molecule assuming multiple crystal structures. [25] Polymorphism can have a 'profound effect on the shelf life, solubility, formulation properties, and processing properties of a drug.' [26] One polymorph of a drug can be more effective than another, easier or more difficult to manufacture, or even dangerous. [27] Polymorphs raise patenting considerations because a company may choose to patent either the molecule's structure, one of its specific crystallized states, or both. Some companies have used polymorphism to their advantage. By patenting a polymorph after the original drug has been patented, a company can extend its period of market exclusivity. [28] However, polymorphism can also present a patenting pitfall. Consider a competitor discovers an unpatented polymorph that is easy to manufacture and is as effective as the original drug. Because it is a polymorph, its production will not infringe on the inventor's patent. Early research to discover a drug's polymorphs and their properties is therefore crucial.
| Conclusion | | |
In summary, it is critical to devise strategies for maximizing patent protection and product lifecycle early in the development process in order to maximize patent term. Such strategies must be developed before patent expiration and prior to the imminent market entry of generic competitors. At the same time, there should be collaboration between scientists and attorneys. For more efficient creation of patents and subsequent protection of their intellectual 'offspring,' pharmaceutical scientists and patent attorneys need to work closely during the lifecycle of the drug to extend its patent life along with the understanding of the underlying concepts and principles of the others' discipline relating to patents.
| Acknowledgment | | |
Authors are thankful to Ms. Aarti Sharma (Jaipur National University, Jaipur, India) for checking the manuscript.
| References | | |
| 1. | Gersten DM. The quest for market exclusivity in biotechnology: Navigating the patent minefield. NeuroRx 2005;2:572-8.  |
| 2. | Grubb PW. Patents for Chemicals, Pharmaceuticals and Biotechnology. In fundamentals of global law, practice and strategy 2 nd ed. London, UK: Oxford University Press; 1999. |
| 3. | Mackenzie M, Keating P, Cambrosio A, Patents and free scientific information in biotechnology: Making monoclonal antibodies proprietary. Sci Tech Hum Values 1990;15:65-83. |
| 4. | A Convergence of Science and Law. National Academy Press. Available from: http://www.nap.edu. [last cited in 2010 Jan 5]. |
| 5. | DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003;22:151-85. |
| 6. | Herper M. Merck announces earnings up 22% per share. Available from:
http://www.forbes.com/ . [last cited in 2000 Oct]. |
| 7. | Pfizer Inc., Pfizer Annual Review 2003. Available from:
http://www.pfizer.com [last cited in 2010 Jan 5]. |
| 8. | 2002 World Pharma sales growth: Slower, but still healthy. (Based on IMS World Review 2003). Available from: http://www.imsglobal.com. [last cited in 2010 Jan 5]. |
| 9. | Top 400 Drugs. Available from:
http://www.pharmalive.com Med Ad Newe. [last cited in 2004]. |
| 10. | Pharmagenerics: Emerging from the shadows of brand power. Available from:
http://www.researchconnect.com
last cited in 2010 Jan 5]. |
| 11. | Pharma Strategies for combating generics. Available from:
http://www.eyeforpharma.com/ . [last cited in 2004 Mar]. |
| 12. | Tuttle E, Parece A, Hector A. Your patent is about to expire: What now? Pharmaceutical Executive [last cited in 2004 Nov]. |
| 13. | Fleming E, Ma P. Drug life-cycle technologies. Nat Rev Drug Discov 2002;1:751-2. |
| 14. | Frear RS. Top Developments on the pharmaceutical landscape 2001: Putting the top developments of 2001 in perspective. Available from: http://www.express-scripts.com [last cited in 2002]. |
| 15. | American Bar Association, Intellectual Property Law, US Patent and Trademark Office: General Information Concerning Patents. Available from:
http://www.abanet.org [last cited in 2010 Jan 5]. |
| 16. |
http://www.docstoc.com/docs/19890301/Global-Pharmaceutical-Industry [last cited in 2010 Mar 14]. |
| 17. | Melethil S. Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney. AAPS J 2005;7:E723-8. |
| 18. | Baeur D. Research/Penn State. The Chiral Quest; 2002. Vol. 23(1).
http://www.rps.psu.edu/0201/chiral.html |
| 19. | U.S. Food and Drug Administration, Center for Drug Evaluation and Research. FDA's Policy Statement for the Development of New Stereoisomeric Drugs. Available from:
http://www.fda.gov/cder/guidance/stereo.htm [last cited in 2010 Jan 5]. |
| 20. | Rouhi MA. Chirality At Work, CENEAR, ISSN 0009-2347, 2003; 81(18): p. 56-61
http://wwwtest1.usm.edu/phillipsgroup/Chirality_at_work.pdf . |
| 21. | Slovakova A. Hutt AJ. Chiral compounds and their pharmacologic effects (in Slovak). Ceska Slov Farm 1999;48:107-12. |
| 22. | NDC Health. The Top 200 Prescriptions for 2003 by US Sales. (Based on data furnished by NDC Health). Available from:
http://www.rxlist.com/top200sales_2003.htm . [last cited in 2010 Jan 5]. |
| 23. | Hutt AJ, Valentovα J. The chiral switch: The development of single enantiomers drugs from racemates, Acta Facult. Pharm. Univ. Comenianae 2003;50:7-23. |
| 24. | Rosack J. Med. Check. Psychiatric News 38:22. Available from: http://
www.pn.psychiatric.online . [last cited in 2010 Jan 5]. |
| 25. | Goho A. Tricky Business. Science News Online. 2004; 166(8):122. Available from:
http://www.sciencenews.org/articles/20040821/bob9.asp . [last accessed on 2005 Jul 25]. |
| 26. | Knapman K. Polymorphic predictions. Mod Drug Discov.3: 2000; 57: 53- 54 Available from:
http://pubs./hotartcl/mdd/00/mar/knap.html . [last accessed on 2005 Jul 25]. |
| 27. | Novartis Pharmaceuticals Corp. v. Eon Labs Manufacturing, Inc., 363 F.3d 1306 (Fed. Cir. CENEAR2004). Kindly provide complete reference |
| 28. | Extends Patent Exclusivity. BioSpace Beat. Available from:
http://www.biospace.com/news_story.cfm?storyID=20215120 , [last accessed on 2005 Jul 25]. |
[Figure 1]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]
| This article has been cited by | | 1 |
Chiral Switch: Between Therapeutical Benefit and Marketing Strategy |
|
| Gabriel Hancu, Adriana Modroiu | | Pharmaceuticals. 2022; 15(2): 240 | | [Pubmed] | [DOI] | | | 2 |
Crystallization of Form II Paracetamol with the Assistance of Carboxylic Acids toward Batch and Continuous Processes |
|
| Kuan-Lin Yeh, Hung-Lin Lee, Tu Lee | | Pharmaceutics. 2022; 14(5): 1099 | | [Pubmed] | [DOI] | | | 3 |
Recent patents on therapeutic activities of xanthohumol: a prenylated chalconoid from hops (Humulus lupulus L.) |
|
| Diwakar Aggarwal, Sushil K Upadhyay, Raj Singh, Hardeep S Tuli | | Pharmaceutical Patent Analyst. 2021; 10(1): 37 | | [Pubmed] | [DOI] | | | 4 |
Growth of Acetaminophen Polymorphic Crystals and Solution-Mediated Phase Transition from Trihydrate to Form II in Agarose Gel |
|
| Akari Nishigaki, Mihoko Maruyama, Shun-ichi Tanaka, Hiroshi Y. Yoshikawa, Masayuki Imanishi, Masashi Yoshimura, Yusuke Mori, Kazufumi Takano | | Crystals. 2021; 11(9): 1069 | | [Pubmed] | [DOI] | | | 5 |
Pharmaceutical patenting in the European Union: reform or riddance |
|
| Livio Garattini, Marco Badinella Martini, Pier Mannuccio Mannucci | | Internal and Emergency Medicine. 2021; | | [Pubmed] | [DOI] | | | 6 |
Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid? |
|
| Livio Garattini, Bruno Finazzi | | Applied Health Economics and Health Policy. 2021; | | [Pubmed] | [DOI] | | | 7 |
Fast 19F Magic Angle Spinning NMR Crystallography for Structural Characterization of Fluorine-Containing Pharmaceutical Compounds |
|
| Changmiao Guo, Matthew P. Fritz, Jochem Struppe, Sebastian Wegner, John Stringer, Ivan V. Sergeyev, Caitlin M. Quinn, Angela M. Gronenborn, Tatyana Polenova | | Analytical Chemistry. 2021; 93(23): 8210 | | [Pubmed] | [DOI] | | | 8 |
Advancements in the Delivery of Growth Factors and Cytokines for the Treatment of Cutaneous Wound Indications |
|
| Caitlin Berry-Kilgour, Jaydee Cabral, Lyn Wise | | Advances in Wound Care. 2021; 10(11): 596 | | [Pubmed] | [DOI] | | | 9 |
Approval policies for modifications to machine learning-based software as a medical device: A study of bio-creep |
|
| Jean Feng, Scott Emerson, Noah Simon | | Biometrics. 2021; 77(1): 31 | | [Pubmed] | [DOI] | | | 10 |
The Effects of Patent Extension and Take-Back Regulation on Green Pharmacy |
|
| Tianqin Shi, Nicholas C. Petruzzi, Dilip Chhajed | | Manufacturing & Service Operations Management. 2021; | | [Pubmed] | [DOI] | | | 11 |
A Critical Discourse Analysis of Intellectual Property Rights Within NAFTA 1.0: Implications for NAFTA 2.0 and for Democratic (Health) Governance in Canada |
|
| Faisal Ali Mohamed, Claudia Chaufan | | International Journal of Health Services. 2020; 50(3): 278 | | [Pubmed] | [DOI] | | | 12 |
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? |
|
| Pavel Klein, Alon Friedman, Mustafa Q. Hameed, Rafal M. Kaminski, Guy Bar-Klein, Henrik Klitgaard, Mathias Koepp, Sergiusz Jozwiak, David A. Prince, Alexander Rotenberg, Roy Twyman, Annamaria Vezzani, Michael Wong, Wolfgang Löscher | | Epilepsia. 2020; 61(3): 359 | | [Pubmed] | [DOI] | | | 13 |
Science and Business of Medicinal Chemistry: A “Bench-to-Bedside” Course for Nonmajors |
|
| Anna G. Wenzel, Steven Casper, Cooper J. Galvin, Grace E. Beck | | Journal of Chemical Education. 2020; 97(2): 414 | | [Pubmed] | [DOI] | | | 14 |
The Polymorphism of Drugs: New Approaches to the Synthesis of Nanostructured Polymorphs |
|
| Dmitry Chistyakov, Gleb Sergeev | | Pharmaceutics. 2020; 12(1): 34 | | [Pubmed] | [DOI] | | | 15 |
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery |
|
| Mario Roberto Senger, Tereza Cristina Santos Evangelista, Rafael Ferreira Dantas, Marcos Vinicius da Silva Santana, Luiz Carlos Saramago Gonçalves, Lauro Ribeiro de Souza Neto, Sabrina Baptista Ferreira, Floriano Paes Silva-Junior | | Memórias do Instituto Oswaldo Cruz. 2020; 115 | | [Pubmed] | [DOI] | | | 16 |
The relationship between medical innovation and health expenditure before and after health reform |
|
| Songul Cinaroglu, Onur Baser | | Health Policy and Technology. 2018; 7(4): 379 | | [Pubmed] | [DOI] | | | 17 |
Intellectual property rights derived from academic research and their role in the modern bioeconomy—A guide for scientists. |
|
| Jan B. Krauss,David Kuttenkeuler | | New Biotechnology. 2017; | | [Pubmed] | [DOI] | | | 18 |
Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it? |
|
| Graham Dutfield | | Health Economics, Policy and Law. 2017; : 1 | | [Pubmed] | [DOI] | | | 19 |
Higher patient satisfaction with antidepressants correlates with earlier drug release dates across online user-generated medical databases |
|
| Scott Siskind,Roland C. Aydin,Punit Matta,Christian J. Cyron | | Pharmacology Research & Perspectives. 2017; 5(5): e00355 | | [Pubmed] | [DOI] | | | 20 |
A systems-level analysis of drug–target–disease associations for drug repositioning |
|
| Kayleigh D. Rutherford,Gaston K. Mazandu,Nicola J. Mulder | | Briefings in Functional Genomics. 2017; | | [Pubmed] | [DOI] | | | 21 |
Between pharmaceutical patents and European patients: is a compromise still possible? |
|
| Livio Garattini,Anna Padula | | Expert Opinion on Therapeutic Patents. 2017; : 1 | | [Pubmed] | [DOI] | | | 22 |
Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products? |
|
| Reed F. Beall,Jason W. Nickerson,Warren A. Kaplan,Amir Attaran,Heinz Fehrenbach | | PLOS ONE. 2016; 11(2): e0148939 | | [Pubmed] | [DOI] | | | 23 |
Has Creative Destruction become more Destructive? |
|
| John Komlos | | The B.E. Journal of Economic Analysis & Policy. 2016; 16(4) | | [Pubmed] | [DOI] | | | 24 |
National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012 |
|
| Meijia Zhou,Matthew Daubresse,Randall S. Stafford,G. Caleb Alexander,Angelo Scuteri | | PLOS ONE. 2015; 10(3): e0119292 | | [Pubmed] | [DOI] | | | 25 |
Tripartite Conflicts of Interest and High Stakes Patent Extensions in the DSM-5 |
|
| Lisa Cosgrove, Sheldon Krimsky, Emily E. Wheeler, Jenesse Kaitz, Scott B. Greenspan, Nicole L. DiPentima | | Psychotherapy and Psychosomatics. 2014; 83(2): 106 | | [Pubmed] | [DOI] | | | 26 |
Product lifecycle management through patents and regulatory strategies |
|
| Vandana Prajapati,Swagat Tripathy,Harish Dureja | | Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing. 2013; 13(3): 171 | | [Pubmed] | [DOI] | | | 27 |
Enantioselectivity of mass spectrometry: Challenges and promises |
|
| Hanan Awad,Anas El-Aneed | | Mass Spectrometry Reviews. 2013; : n/a | | [Pubmed] | [DOI] | | | 28 |
Necessity of Establishing Chemical Integrity of Polymorphs of Drug Substance Using a Combination of NMR, HPLC, Elemental Analysis, and Solid-State Characterization Techniques: Case Studies |
|
| Kamlesh D. Sawant,Tushar A. Naik | | Organic Process Research & Development. 2013; 17(3): 519 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
